AstraZeneca to stop developing Crohn's disease drug
Send a link to a friend
[June 01, 2023]
(Reuters) - British drugmaker AstraZeneca said on Thursday it
would stop developing its drug brazikumab to treat inflammatory bowel
diseases, including Crohn's disease and ulcerative colitis.
The company said the discontinuation was due to a delay in the drug's
development timeline, affected by global events and "the context of a
competitive landscape".
AstraZeneca regained the rights to brazikumab from Allergan in 2020
following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.
AbbVie will stop funding the drug's development, AstraZeneca said.
[to top of second column]
|
![](../images/060123PIX/health71.jpg)
Test tubes are seen in front of a
displayed AstraZeneca logo in this illustration taken, May 21, 2021.
REUTERS/Dado Ruvic/Illustration/File Photo
![](http://archives.lincolndailynews.com/2023/Jun/01/images/ads/current/flossie_sda_PROMGRAD_2023.png) AbbVie's Skyrizi also treats Crohn's disease.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D'Souza)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |